The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index; 14 of the 25 sources its claims cite were checked for support.
CONSORT 2025 statement: Updated guideline for reporting randomised trials
Open accessAbstract
Background: Well designed and properly executed randomised trials are considered the most reliable evidence on the benefits of healthcare interventions. However, there is overwhelming evidence that the quality of reporting is not optimal. The CONSORT (Consolidated Standards of Reporting Trials) statement was designed to improve the quality of reporting and provides a minimum set of items to be included in a report of a randomised trial. CONSORT was first published in 1996, then updated in 2001 and 2010. Here, we present the updated CONSORT 2025 statement, which aims to account for recent methodological advancements and feedback from end users. Methods: We conducted a scoping review of the literature and developed a project-specific database of empirical and theoretical evidence related to CONSORT, to generate a list of potential changes to the checklist. The list was enriched with recommendations provided by the lead authors of existing CONSORT extensions (Harms, Outcomes, Non-pharmacological Treatment), other related reporting guidelines (TIDieR) and recommendations from other sources (e.g., personal communications). The list of potential changes to the checklist was assessed in a large, international, online, three-round Delphi survey involving 317 participants and discussed at a two-day online expert consensus meeting of 30 invited international experts. Results: We have made substantive changes to the CONSORT checklist. We added seven new checklist items, revised three items, deleted one item, and integrated several items from key CONSORT extensions. We also restructured the CONSORT checklist, with a new section on open science. The CONSORT 2025 statement consists of a 30-item checklist of essential items that should be included when reporting the results of a randomised trial and a diagram for documenting the flow of participants through the trial. To facilitate implementation of CONSORT 2025, we have also developed an expanded version of the CONSORT 2025 checklist, with bullet points eliciting critical elements of each item. Conclusions: Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomised trials to ensure that trial reports are clear and transparent.
Overview
CoChat Summary
TL;DR
CONSORT 2025 is an updated reporting guideline for randomised trial reports, replacing CONSORT 2010 with a 30-item checklist and revised flow diagram. It adds seven items, revises three, deletes one, integrates items from key CONSORT extensions, and introduces an open science section.
Key findings
- The CONSORT 2025 checklist contains 30 items and includes a new open science section covering trial registration, protocol/statistical analysis plan access, data sharing, and funding/conflicts of interest.
- The update added seven new checklist items, revised three items, deleted one item, and integrated several items from CONSORT extensions (Harms, Outcomes, Non-pharmacological Treatment) and TIDieR.
- New items address data sharing (item 4), author conflicts of interest (item 5b), patient/public involvement (item 8), site/intervention-deliverer eligibility (item 12b), harms assessment (item 15), analysis populations and missing data (items 21b, 21c), and intervention/comparator delivery and concomitant care (items 24a, 24b).
- An expanded version of the checklist was developed with bullet points eliciting critical elements of each item.
Methods
- The update followed EQUATOR Network guidance and used a scoping review, a project-specific database (SCEBdb), and recommendations from lead authors of key CONSORT extensions, TIDieR, and other sources.
- A three-round international online Delphi survey involved 317 participants in round 1, 303 in round 2, and 290 in round 3; participants rated item inclusion on a 5-point Likert scale.
- A two-day online expert consensus meeting of 30 invited international experts discussed the Delphi results, followed by a two-day in-person executive writing meeting in Oxford on 25–26 April 2023.
Limitations
- The paper states that CONSORT 2025 and SPIRIT 2025 do not include recommendations for designing, conducting, or analysing trials, and that CONSORT 2025 is not meant to be used as a quality assessment instrument.
- The paper states that CONSORT 2025 focuses on the most common two-group parallel design and that existing CONSORT extensions have not yet been aligned with CONSORT 2025; readers are advised to use existing relevant extensions in the meantime.
- Evident from the text: no formal consensus threshold was specified for the advisory Zoom polls at the expert consensus meeting, and the guideline is described as a living guideline that will be periodically updated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
10 Valid · 1 Not valid · 5 Not checked · 34 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“extensive evidence displays that the completeness of reporting of randomised trials is inadequate [2,3]”
- Also stated in: § Background · boosted
“there is overwhelming evidence that the quality of reporting is not optimal”
§ CONSORT 2025 statement: Updated guideline for reporting randomised trials > Introduction
What the sources say
- Supportedcites [2] L Turner, 2012, Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review, Syst Rev source
The Discussion says that inadequate reporting of essential elements in RCT reports hinders systematic reviews. It also describes problems in research reporting as systemic and widespread, supporting the citing sentence's broad characterization. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [3] P Glasziou, 2014, Reducing waste from incomplete or unusable reports of biomedical research, Lancet source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Background · boosted
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A Cochrane review of 50 evaluations of 16,604 trials assessed the association between journals’ endorsement of CONSORT and the reporting of trials they published; 25 of 27 CONSORT checklist items were more completely reported when a trial was published in a CONSORT endorsing as opposed to non-endorsing journal [2,14].”
§ CONSORT 2025 statement: Updated guideline for reporting randomised trials > Introduction
What the sources say
- Supportedcites [2] L Turner, 2012, Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review, Syst Rev source
The Abstract’s Results report 50 evaluations covering 16,604 RCTs. The Results section on endorsing versus non-endorsing journals says that 25 of 27 outcomes had effect estimates favouring more complete reporting in endorsing journals, although only five were statistically significant at the 1% level. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [14] A Dechartres, 2017, Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study, BMJ source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The methods used to update the CONSORT statement followed the EQUATOR Network guidance for developers of health research guidelines [19] and have been described in detail elsewhere [20,21].”
§ CONSORT 2025 statement: Updated guideline for reporting randomised trials > Development of CONSORT 2025
What the sources say
- Supportedcites [19] D Moher, 2010, Guidance for developers of health research reporting guidelines, PLoS Med source
The Discussion identifies this paper as guidance for developing reporting guidelines. In ‘18. Update Guideline,’ the authors describe their CONSORT update meeting and use the CONSORT 2010 revision to illustrate the guidance. The cited paper is therefore the guidance identified in the sentence and connects it to CONSORT updating. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Some evidence shows that journal endorsement of CONSORT is associated with better reporting and that reporting is improving over time [2,13–15].”
- Also stated in: § Introduction · plain
“The introduction of CONSORT within journals has been shown to be associated with improved quality of reports of randomised trials.”
§ CONSORT 2025 statement: Updated guideline for reporting randomised trials > Introduction
What the sources say
- Supportedcites [2] L Turner, 2012, Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review, Syst Rev source
The Results section compares CONSORT-endorsing with non-endorsing journals and reports more complete RCT reporting in endorsing journals for 25 of 27 outcomes, five significantly so. This supports the attributed association; it does not require a causal interpretation. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [13] AC Plint, 2006, Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review, Med J Aust source
- Not checked — no full text of the sourcecites [14] A Dechartres, 2017, Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study, BMJ source
- Not checked — no full text of the sourcecites [15] CONSORT Group (Consolidated Standards for Reporting of Trials), 2001, Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation, JAMA source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
In the paper
“incomplete reporting may be associated with biased estimates of intervention effects [4]”
§ CONSORT 2025 statement: Updated guideline for reporting randomised trials > Introduction
What the sources say
- Not checked — no full text of the sourcecites [4] J Savović, 2012, Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials, Ann Intern Med source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
2 more claims
Create a free account to see all 50 claims and every source verdict.
- Probably not a substantial claim. 43
- It may state two separate claims as one. 18
Citations
Cites
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874 · cited 1×
“This is similar to the model proposed by the COBWEB (CONSORT-based web tool) PLOS Medicine [30] and COBPeer (CONSORT based peer review tool) [31] studies and used in the 2020 PRISMA guidance for reporting systematic reviews [32].”
Self-citationHoffmann, T. C., Glasziou, P. P., Boutron, I., Milne, R., Perera, R., Moher, D., Altman, D. G., Barbour, V., Macdonald, H., Johnston, M., et al. (2014) · BMJ · doi:10.1136/bmj.g1687 · Cited by 10,548 · cited 3×
“…all trials (Harms [24], Outcomes [25]), or a considerable number of trials [26] (Non-pharmacological Treatment [27]), other related reporting guidelines (the template for intervention description and replication (TIDieR) [28]), and recommendations from other sources (e.g., personal communications).”
Self-citationMoher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883 · cited 2×
“CONSORT was then updated in 2010 [9], along with an updated explanation and elaboration article [10].”
Self-citationSPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · cited 1×
“…transparent reporting of trial protocols led to the development of the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement, published in 2013 [11], and its accompanying explanation and elaboration document [12] explaining the principles underlying the statement.”
Self-citationSPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251 · cited 1×
“…transparent reporting of trial protocols led to the development of the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement, published in 2013 [11], and its accompanying explanation and elaboration document [12] explaining the principles underlying the statement.”
Self-citationThe Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835 · cited 1×
“Those initiatives then led to publication of the CONSORT (Consolidated Standards of Reporting Trials) statement in 1996 [6], revised in 2001 [7] with an accompanying explanation and elaboration document [8].”
Self-citationCONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Self-citationConsort 2010 statement: extension to cluster randomised trials
Campbell, M. K., Piaggio, G., Elbourne, D. R., Altman, D. G., & for the CONSORT Group (2012) · BMJ · doi:10.1136/bmj.e5661 · Cited by 3,510 · cited 1×
“Examples of extensions for trial designs include recommendations for adaptive designs [33], cluster trials [34], crossover trials [35], early phase trials [36], factorial trials [37], non-inferiority and equivalence trials [38], pragmatic trials [39], multi-arm trials [40], n-of-1 trials [41],…”
Self-citationCONSORT 2010 statement: extension to randomised pilot and feasibility trials.
Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L., & Lancaster, G. A. (2016) · BMJ · doi:10.1136/bmj.i5239 · Cited by 3,404
Self-citationImproving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Cited by
SPIRIT 2025 statement: Updated guideline for protocols of randomised trials
Chan, A., Boutron, I., Hopewell, S., Moher, D., Schulz, K. F., Collins, G. S., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004589 · Cited by 113
“Here, we introduce the updated SPIRIT 2025 statement; the CONSORT 2025 statement is published separately [16].”
Self-citationEuropean Resuscitation Council Guidelines 2025 Ethics in Resuscitation
Raffay, V. I., Wittig, J., Bossaert, L. L., Djakow, J., Djärv, T., Estella, Á., Lulić, I., Mentzelopoulos, S. D., Monsieurs, K. G., de Voorde, P. V., et al. (2025) · Resuscitation · doi:10.1016/j.resuscitation.2025.110734 · Cited by 79
Aharoni-Frutkoff, Y., Плоткин, Л. Л., Pollak, D., Livovsky, J., Focht, G., Lev‐Tzion, R., Ledder, O., Assa, A., Yogev, D., Orlanski‐Meyer, E., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.011 · Cited by 39
Sampling Methods and Sample Size Determination in Clinical Research: An Educational Review
Zrineh, A., Al‐Usta, M., & Alwawi, A. A. (2026) · Journal of General and Family Medicine · doi:10.1002/jgf2.70096 · Cited by 67
“Prominent reporting guidelines such as CONSORT [33] and STROBE [34] also mandate this, emphasizing that a justified sample size enhances a study's credibility and the reliability of findings.”
Dominitz, J. A., Ladabaum, U., Holub, J. L., Issaka, R. B., Ko, C. W., & Robertson, D. J. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.009 · Cited by 13
Metadata
- Authors
- Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., Bhandari, N., Butcher, N. J., Campbell, M. K., Chidebe, R. C. W., Elbourne, D., Farmer, A., Fergusson, D. A., Golub, R. M., Goodman, S. N., Hoffmann, T. C., Ioannidis, J. P. A., Kahan, B. C., Knowles, R. L., Lamb, S. E., Lewis, S., Loder, E., Offringa, M., Ravaud, P., Richards, D. P., Rockhold, F. W., Schriger, D. L., Siegried, N. L., Staniszewska, S., Taylor, R. S., Thabane, L., Torgerson, D., Vohra, S., White, I. R., & Boutron, I.
- Affiliations
- University of Oxford (GB)
- University of Toronto (CA)
- University of Southern Denmark (DK)
- Ottawa Hospital Research Institute (CA)
- University of North Carolina at Chapel Hill (US)
- Jawaharlal Institute of Post Graduate Medical Education and Research (IN)
- Centers for Disease Control and Prevention (US)
- Rutgers, The State University of New Jersey (US)
- Society for Applied Studies (IN)
- University of Aberdeen (GB)
- Miami University (US)
- London School of Hygiene & Tropical Medicine (GB)
- Northwestern University (US)
- Stanford University (US)
- Bond University (AU)
- MRC Clinical Trials Unit at UCL (GB)
- University College London (GB)
- University of Exeter (GB)
- University of Edinburgh (GB)
- Harvard University (US)
- Hospital for Sick Children (CA)
- Inserm (FR)
- MaRS (CA)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- University of Warwick (GB)
- MRC/CSO Social and Public Health Sciences Unit (GB)
- St. Joseph’s Healthcare Hamilton (CA)
- University of York (GB)
- University of Alberta (CA)
- Corresponding author
- Hopewell, Sally
- ORCID
- Hopewell, Sally
- Chan, An-Wen
- Collins, Gary S.
- Hróbjartsson, Asbjørn
- Moher, David
- Schulz, Kenneth F.
- Tunn, Ruth
- Aggarwal, Rakesh
- Berkwits, Michael
- Berlin, Jesse A.
- Bhandari, Nita
- Butcher, Nancy J.
- Campbell, Marion K.
- Chidebe, Runcie C. W.
- Elbourne, Diana
- Farmer, Andrew
- Fergusson, Dean A.
- Golub, Robert M.
- Goodman, Steven N.
- Hoffmann, Tammy C.
- Ioannidis, John P. A.
- Kahan, Brennan C.
- Knowles, Rachel L.
- Lamb, Sarah E.
- Lewis, Steff
- Loder, Elizabeth
- Offringa, Martin
- Ravaud, Philippe
- Richards, Dawn P.
- Rockhold, Frank W.
- Schriger, David L.
- Siegried, Nandi L.
- Staniszewska, Sophie
- Taylor, Rod S.
- Thabane, Lehana
- Torgerson, David
- Vohra, Sunita
- White, Ian R.
- Boutron, Isabelle
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2025-04-14
- Volume
- 22
- Issue
- 4
- Pages
- e1004587
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC11996237
- OpenAlex
- W4409424632
- Cited by
- 139
- References
- 52
- Citations by year
- 2026: 72 · 2025: 67
- FWCI
- 88.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
- Bond University Research Portal (Bond University) (submittedVersion, cc-by)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Medical Research Council (MR/W020483/1)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Sociology and Political Science › Delphi Technique in Research
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- reporting guidelines, randomised trials, trial reporting quality, CONSORT checklist, CONSORT extension, harms reporting, non-pharmacological treatment, open science, flowcharts, TIDieR, Delphi consensus
- MeSH terms
- Delphi Technique, Humans, Publishing, Research Design, Randomized Controlled Trials as Topic, Guidelines as Topic, Checklist, Research Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CONSORT 2025 statement: Updated guideline for reporting randomised trials. https://app.cochat.ai/papers/10.1371/journal.pmed.1004587
- The paper
- Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., Bhandari, N., Butcher, N. J., Campbell, M. K., Chidebe, R. C. W., Elbourne, D., Farmer, A., Fergusson, D. A., Golub, R. M., Goodman, S. N., . . . Boutron, I. (2025). CONSORT 2025 statement: Updated guideline for reporting randomised trials. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004587
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
